RUBY VARKEY: Open Payments
NPI 1851951222 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$872 in 18 payments from 9 companies in 2025. Trend: 2023 $356 · 2024 $810 · 2025 $872
Food & beverage: $835Education: $37
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $305 |
| PFIZER INC. | 3 | $182 |
| SOBI, INC | 1 | $115 |
| Syndax Pharmaceuticals, Inc. | 2 | $64 |
| JAZZ PHARMACEUTICALS INC. | 1 | $60 |
| ABBVIE INC. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Janssen Biotech, Inc. | 1 | $32 |
| Incyte Corporation | 1 | $28 |
Products named: Xospata, ELREXFIO, Vonjo, Cresemba, DEFITELIO, EPKINLY, LIVTENCITY, DARZALEX.
Industry payments across TX — which companies pay providers there.
